[Pravastatin in hypercholesterolemia in the elderly. Increase of the caseload and control of the results with a regional study on the elderly population of the Monfalcone and Grado areas].
The authors confirm--by increasing the ambulatory randomized series in the territories which depend on Monfalcone and Grado (USL 2 Goriziana)--the results of previous studies of lipid improvement owing to the use of pravastatine. The average cholesterolemic rate has decreased of 26.50% in comparison with the initial value, that is from 310.44 +/- 52.587 mg% to 228.16 +/- 28.354 mg%; the addition of each individual rate from 19868 mg% to 14602 mg% (p < 0.001). Within the sample, the elder's undergroup reduced blood cholesterol by 25.76%, that is from 307.69 +/- 42.057 mg% to 228.44 +/- 28.126 mg%, with an addition from 13846 mg% to 10280 mg% (p < 0.001); the adults' undergroup of 28.26%, that is from 316.95 +/- 72.744 mg% to 227.47 +/- 29.654 mg%, with an addition from 6022 mg% to 4322 mg% (p < 0.001). The LDL-lipoprotein value showed a decrease from 30.66% in the average value, which lowered from 206.87 +/- 51.485 to 143.43 +/- 32.940 mg% (relative addition from 13239 mg% to 9179 mg%); in the old patients from 211.45 +/- 52.758 mg% to 143.66 +/- 35.654 mg% (relative addition from 9515 mg% to 6465 mg%), in the adults from 196.01 +/- 47.923 mg% to 142.86 +/- 26.264 mg% (relative addition from 3724 mg% to 2714 mg%. Triglyceridemia fell from 38.37%; the average circulating value fell from 245.13 +/- 348.415 mg% to 151.08 +/- 130.347 mg%; the complete series showed the same average decrease ie from 15688 mg% to 9669 mg%. In the elderly we showed a reduction from 207.87 +/- 250.784 mg% to 149.91 +/- 144.606 mg% (relative addition from 9354 mg% to 6746 mg%), in adults from 333.37 +/- 509.360 mg% to 153.846 +/- 91.321 mg% (relative addition from 6334 mg% to 2923 mg%).